Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival A Large Cohort Study of the German Network for Systemic Sclerosis

被引:8
|
作者
Moinzadeh, Pia [1 ]
Bonella, Francesco [2 ]
Oberste, Max [3 ]
Weliwitage, Jithmi [3 ]
Blank, Nobert [4 ]
Riemekasten, Gabriela [5 ]
Mueller-Ladner, Ulf [6 ]
Henes, Joerg [7 ]
Siegert, Elise [8 ,9 ]
Guenther, Claudia [10 ]
Koetter, Ina [11 ,12 ]
Pfeiffer, Christiane [13 ]
Schmalzing, Marc [14 ]
Zeidler, Gabriele [15 ]
Korsten, Peter [16 ]
Susok, Laura [17 ]
Juche, Aaron [18 ]
Worm, Margitta [19 ]
Jandova, Ilona [20 ]
Ehrchen, Jan [21 ]
Sunderkoetter, Cord [22 ]
Keysser, Gernot [23 ]
Ramming, Andreas [24 ,25 ]
Schmeiser, Tim [26 ]
Kreuter, Alexander [27 ]
Lorenz, Hanns-Martin [4 ]
Hunzelmann, Nicolas [1 ]
Kreuter, Michael [28 ,29 ]
机构
[1] Univ Hosp Cologne, Dept Dermatol & Venereol, Cologne, Germany
[2] Univ Duisburg Essen, Pneumonol Dept, Ctr Interstitial & Rare Lung Dis, Ruhrlandklin, Essen, Germany
[3] Univ Hosp Cologne, Inst Med Stat & Computat Biol, Fac Med, Cologne, Germany
[4] Univ Hosp Heidelberg, Div Rheumatol, Internal Med 5, Heidelberg, Germany
[5] Univ Lubeck, Univ Hosp Schleswig Holstein, Clin Rheumatol & Clin Immunol, D-23562 Lubeck, Germany
[6] Kerckhoff Clin & Fdn, Dept Rheumatol, D-61231 Bad Nauheim, Germany
[7] Univ Hosp Tubingen, Ctr Interdisciplinary Rheumatol Clin Immunol & Au, Tubingen, Germany
[8] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[9] Berlin Inst Hlth, Berlin, Germany
[10] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany
[11] Univ Hosp Hamburg Eppendorf, Div Rheumatol & Syst Inflammatory Dis, Hamburg, Germany
[12] Rheumatol Clin Bad Bramstedt, Bad Bramstedt, Germany
[13] Univ Med Ctr Ulm, Dept Dermatol & Allergol, Ulm, Germany
[14] Univ Hosp Wurzburg, Dept Internal Med 2, Rheumatol Clin Immunol, Wurzburg, Germany
[15] Johanniter Hosp Treuenbrietzen, Ctr Rheumatol Brandenburg, Dept Rheumatol Osteol & Pain Therapy, Treuenbrietzen, Germany
[16] Univ Med Ctr Gottingen, Dept Nephrol & Rheumatol, Gottingen, Germany
[17] St Josef Hosp, Dept Dermatol Venereol & Allergol, Bochum, Germany
[18] Immanuel Krankenhaus Berlin, Dept Rheumatol, D-13125 Berlin, Germany
[19] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, DE-10117 Berlin, Germany
[20] Univ Med Ctr Freiburg, Rheumatol & Clin Immunol, Freiburg, Germany
[21] Univ Hosp Munster, Dept Dermatol, Munster, Germany
[22] Univ Hosp Halle Saale, Dept Dermatol, Halle, Saale, Germany
[23] Univ Hosp Halle Saale, Div Rheumatol, Internal Med, Halle, Saale, Germany
[24] Friedrich Alexander Univ FAU Erlangen Nurnberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[25] Univ Hosp Erlangen, Erlangen, Germany
[26] Hosp St Josef, Internal Med Rhematol & Osteol, Wuppertal, Germany
[27] Univ Witten Herdecke, Helios St Elisabeth Hosp Oberhausen, Dept Dermatol Venereol & Allergol, Oberhausen, Germany
[28] Mainz Univ Med Ctr, Mainz Ctr Pulm Med, Dept Pneumol, Mainz, Germany
[29] Marienhaus Clin Mainz, Dept Pulm Crit Care & Sleep Med, Mainz, Germany
关键词
ILD; ILD-PH; ILD-w/o-PH; interstitial lung disease; overall survival; PAH; PH; pulmonary hypertension; scleroderma; SSc; survival; systemic sclerosis; ARTERIAL-HYPERTENSION; PREDICTING MORTALITY; SCLERODERMA; CLASSIFICATION; METAANALYSIS; PROGRESSION; MANAGEMENT; DIAGNOSIS; SUBSETS;
D O I
10.1016/j.chest.2023.08.013
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: Pulmonary involvement is the leading cause of death in systemic sclerosis (SSc) and may manifest as interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), or in combination of both (ILD with pulmonary hypertension [ILD -PH]). The aim of this analysis was to determine prevalence, clinical characteristics, and survival of these different forms within the registry of the German Network for Systemic Sclerosis. RESEARCH QUESTION: Does SSc-associated ILD -PH or ILD without PH affect survival differently, and are there any risk factors that have an additional impact? STUDY DESIGN AND METHODS: Clinical data of 5,831 patients with SSc were collected in the German Network for Systemic Sclerosis registry. Kaplan -Meier estimates were used to compare overall survival in patients with SSc-associated ILD -PH and ILD without PH with patients without pulmonary involvement and those with PAH. The Cox proportional hazard model was used to analyze the influence of pulmonary involvement and other potential predictors on patient survival. RESULTS: Clinical data of 3,257 patients with a mean follow-up time of 3.45 +/- 1.63 years have been included in our analysis. At baseline, ILD was present in 34.5%, whereas PH without ILD had a lower prevalence with 4.5%. At the end of follow-up, 47.6% of patients with SSc had ILD, 15.2% had ILD -PH, and 6.5% had PAH. ILD was more frequent in the diffuse cutaneous form (57.3%), whereas PAH did not differ significantly between SSc subtypes. Significant differences in baseline characteristics between PAH vs ILD -PH vs ILD without PH were found for age at diagnosis, sex, SSc subsets, antibody status, FVC, diffusing capacity of the lung for carbon monoxide, and therapy. Overall survival at 5 years was 96.4% for patients without pulmonary involvement and differed significantly between patients with ILD without PH, PAH, and being worst in patients with ILD-PH. Female sex (hazard ratio [HR], 0.3), higher BMI (HR, 0.9), and higher diffusing capacity of the lung for carbon monoxide values (HR, 0.98) were associated with a lower mortality risk. INTERPRETATION: ILD is the most prevalent pulmonary involvement in SSc, whereas the combination of ILD and PH is associated with the most detrimental survival.
引用
收藏
页码:132 / 145
页数:14
相关论文
共 50 条
  • [31] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Athanasios Koutroumpas
    Athanasios Ziogas
    Ioannis Alexiou
    Georgia Barouta
    Lazaros I. Sakkas
    Clinical Rheumatology, 2010, 29 : 1167 - 1168
  • [32] Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    Koutroumpas, Athanasios
    Ziogas, Athanasios
    Alexiou, Ioannis
    Barouta, Georgia
    Sakkas, Lazaros I.
    CLINICAL RHEUMATOLOGY, 2010, 29 (10) : 1167 - 1168
  • [33] Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
    Yamasaki, Yoshioki
    Kuwana, Masataka
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (06) : 547 - 560
  • [34] Systemic sclerosis-associated interstitial lung disease treated with tocilizumab
    Dauny, Vincent
    Borie, Raphael
    Forien, Marine
    Ghanem, Mada
    Palazzo, Elisabeth
    Jelin, Germain
    Dieude, Philippe
    Ottaviani, Sebastien
    INTERNAL MEDICINE JOURNAL, 2021, 51 (06) : 999 - 1000
  • [35] Responses to exercise in systemic sclerosis-associated interstitial lung disease
    Donnelly, Ronan P.
    Smyth, Anita E.
    Mullan, Charles
    Riley, Marshall S.
    Nicholls, D. Paul
    CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING, 2023, 43 (04) : 253 - 262
  • [36] Pleuroparenchymal fibroelastosis in systemic sclerosis-associated interstitial lung disease
    Sari, Alper
    Onder, Omer
    Armagan, Berkan
    Bolek, Ertugrul Cagri
    Farisogullari, Bayram
    Bilgin, Emre
    Yardimci, Gozde Kubra
    Ariyurek, Macit
    Akdogan, Ali
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2022, 52 (01) : 83 - 88
  • [37] Molecular Insights Into Systemic Sclerosis-Associated Interstitial Lung Disease
    Silver, Richard M.
    Feghali-Bostwick, Carol A.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 (03) : 485 - 487
  • [38] Current treatment of systemic sclerosis-associated interstitial lung disease
    Bes, Cemal
    Cetinkaya, Erdogan
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2022, 70 (01): : 85 - 92
  • [39] Incidence and prevalence of Systemic Sclerosis-associated Interstitial Lung Disease in a multicenter prospective cohort study
    Vandecasteele, Els
    Melsens, Karin
    Blockmans, Daniel
    Carton, Charlotte
    De Keyser, Filip
    De Langhe, Ellen
    Lauwerys, Bernard
    Piette, Yves
    Vanhaecke, Amber
    Verbeke, Koen
    Wuyts, Wim
    Brusselle, Guy
    Smith, Vanessa
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [40] PROGRESSIVE INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Cuomo, G.
    Di Vico, C.
    Perretta, D.
    Iandoli, C.
    Ciaburri, R.
    Adamo, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1657 - 1658